Boston Scientific (BSX) Downgraded by Zacks Investment Research

Adjust Comment Print

About 82.32M shares traded or 2.27% up from the average. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider's stock valued at $138,928,000 after purchasing an additional 2,850,630 shares in the last quarter. Us Bancorp Del now has $94.54B valuation.

The Stock declined-0.04% and closed its last trading session at $187.77. The stock was purchased at an average price of $0.45 per share, for a total transaction of $183,602.70. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since January 11, 2017 and is uptrending. It has outperformed by 6.37% the S&P500.

Investors sentiment increased to 1.19 in Q3 2017. Its up 0.01, from 1.03 in 2017Q2. 81 funds opened positions while 281 raised stakes. C Grp Inc Hldgs A S holds 0.15% or 367,194 shares. The fund owned 36,765 shares of the medical equipment provider's stock after selling 5,058 shares during the quarter. Louisiana State Employees Retirement Sys owns 85,700 shares for 0.12% of their portfolio. Piedmont Inv Advsr Limited Co invested in 0.01% or 6,406 shares. Washington Bank owns 200 shares or 0% of their USA portfolio. Moreover, Griffin Asset Mngmt has 0.67% invested in U.S. Bancorp (NYSE:USB). Creative Planning stated it has 43,996 shares. Teacher Retirement System Of Texas acquired 127,112 shares as Ecolab Inc (ECL)'s stock rose 2.53%. Corporate insiders own 1.31% of the company's stock. Moreover, Rathbone Brothers Public Lc has 1.33% invested in General Electric Company (NYSE:GE) for 1.26M shares. Chevy Chase Tru Holdg Inc invested 0.37% of its portfolio in U.S. Bancorp (NYSE:USB). Dimensional Fund Advisors Limited Partnership invested in 0.02% or 1.07M shares.

Stephens Investment Management Group Llc, which manages about $3.08B and $4.34B US Long portfolio, decreased its stake in Take (NASDAQ:TTWO) by 8,977 shares to 626,668 shares, valued at $64.06 million in 2017Q3, according to the filing. It also reduced its holding in Pfizer Inc (NYSE:PFE) by 20,157 shares in the quarter, leaving it with 35,407 shares, and cut its stake in Epam Systems (NYSE:EPAM). Global Payments Inc. (NYSE:GPN) was raised too. On Wednesday, August 30 the insider Nanavaty Maulik sold $1.56M. 5 analysts say it's a Hold while 0 analysts provided their expert opinion as Sell. Therefore 78% are positive. Sarepta Therapeutics had 95 analyst reports since August 5, 2015 according to SRatingsIntel. Canaccord Genuity maintained the stock with "Buy" rating in Wednesday, November 29 report. The stock has "Sell" rating by Deutsche Bank on Friday, May 12. As per Wednesday, June 28, the company rating was maintained by Barclays Capital. The rating was upgraded by Portales Partners on Tuesday, August 25 to "Sector Perform". The rating was upgraded by CLSA on Thursday, October 1 to "Strong Buy". The company was maintained on Tuesday, July 25 by Morgan Stanley. This showed a surprise of 0% in the last quarter earnings. DnB Asset Management AS now owns 151,150 shares of the medical equipment provider's stock valued at $3,747,000 after purchasing an additional 17,500 shares in the last quarter.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, October 26th. Primecap Ca has invested 1.02% in Boston Scientific Corporation (NYSE:BSX). BSX's profit will be $466.89 million for 20.17 P/E if the $0.34 EPS becomes a reality.

Watch South Africa vs India on TV, online
He outlined the differentiation in his performance was down to understanding the nature of the pitches here. Don't forget the year 2017 belonged to both Kohli and Rohit, who had shone across the formats.


Boston Scientific Corporation (BSX) now trades with a market capitalization of $38.36 Billion. 25 were sells. Insider ownership decreased by a total of 190930 shares, which suggests that BSX's key executives are feeling less optimistic about the outlook for the stock. Also, EVP Timothy A. Pratt sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, November 1st. Pierce David A also sold $243,074 worth of Boston Scientific Corporation (NYSE:BSX) on Thursday, January 11. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider's stock worth $84,337,000 after buying an additional 3,033,800 shares in the last quarter.

The opening price for Boston Scientific Corporation (NYSE:BSX) was $27.7 and the volume amounted to 13.01 million shares which compares with the average volume of 8.72 million shares. Shares for $208,328 were sold by Sorenson John Bradley. Comstock Elizabeth J sold $633,375 worth of General Electric Company (NYSE:GE) on Wednesday, August 9.

Among 29 analysts covering Boston Scientific Corporation (NYSE:BSX), 23 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company's stock. The company was maintained on Monday, June 26 by BTIG Research. The rating was downgraded by CL King to "Buy" on Wednesday, October 28. Citigroup initiated the stock with "Buy" rating in Thursday, November 12 report. The firm earned "Outperform" rating on Friday, December 16 by Bernstein. The firm has "Hold" rating by Jefferies given on Friday, July 29. The stock has "Buy" rating by RBC Capital Markets on Monday, October 2. RBC Capital Markets has "Outperform" rating and $31 target.

Artisan Partners Limited Partnership increased its position in shares of Boston Scientific Corporation by 1.1% in the second quarter. The firm has a market cap of $34.34 billion, a price-to-earnings ratio of 475.85 and a beta of 1.06. The investor is now holding $52.33 million shares due in part to a decrease of 2.07 million new shares in their portfolio. 213.37 million shares or 1.11% more from 211.02 million shares in 2017Q2 were reported.

Comments